Giovanna Zorzi

Dr. Giovanna Zorzi

orcid

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
JGJessica Garau
Jessica Garau
VCVanessa Cavallera
Vanessa Cavallera
MVMarialuisa Valente Valente
Marialuisa Valente Valente
DTDavide Tonduti
Davide Tonduti
DSDaisy Sproviero
Daisy Sproviero
CCCristina Cereda
Cristina Cereda
Aicardi-Goutières syndrome (AGS) is a genetically determined early onset encephalopathy characterized by cerebral calcification, leukodystrophy, and increased expression of interferon-stimulated genes (ISGs). Up to now, seven genes (TREX1, RNASEH2B, RNASEH2C, RNASEH2A, ADAR1, SAMHD1, IFIH1) have been associated with an AGS phenotype. Next Generation Sequencing (NGS) analysis was performed on 51 AGS patients and interferon signature (IS) was investigated in 18 AGS patients and 31 healthy controls. NGS identified mutations in 48 of 51 subjects, with three patients demonstrating a typical AGS phenotype but not carrying mutations in known AGS-related genes. Five mutations, in RNASEH2B, SAMHD1 and IFIH1 gene, were not previously reported. Eleven patients were positive and seven negatives for the upregulation of interferon signaling (IS > 2.216). This work presents, for the first time, the genetic data of an Italian cohort of AGS patients, with a higher percentage of mutations in RNASEH2B and a lower frequency of mutations in TREX1 than those seen in international series. RNASEH2B mutated patients showed a prevalence of negative IS consistent with data reported in the literature. We also identified five novel pathogenic mutations that warrant further functional investigation. Exome/genome sequencing will be performed in future studies in patients without a mutation in AGS-related genes.

14 August 2013 in Orphanet Journal of Rare Diseases
Verified
Journal Article
Open access
PDF file
LNLorenzo Nanetti
Lorenzo Nanetti
SCSimona Cavalieri
Simona Cavalieri
VPViviana Pensato
Viviana Pensato
AEAlessandra Erbetta
Alessandra Erbetta
DPDavide Pareyson
Davide Pareyson
CMCaterina Mariotti
Caterina Mariotti
Objectives/background: Ataxia with oculomotor apraxia defines a group of genetically distinct recessive ataxias including ataxia-telangectasia (A-T,ATMgene), ataxia with oculomotor apraxia type 1 (AOA1,APTXgene) and type 2 (AOA2,SETXgene). Although, a few unique clinical features differentiate each of these forms, the patients also share common clinical signs, such as the presence of cerebellar atrophy, sensorimotor axonal neuropathy, and elevated alpha-fetoprotein (AFP) serum level.Materials and methods: We selected 22 Italian patients from 21 families, presenting progressive cerebellar ataxia, axonal neuropathy, and elevated serum AFP. We screened the coding regions ofATM,APTXandSETXgenes for point mutations by direct sequencing or DHPLC, and searched genomic rearrangements inSETXby MLPA analysis. In selected cases, quantification of ATM and senataxin proteins was performed by Western blot. Clinical, neurophysiological, and neuroimaging data were collected.Results: Thirteen patients (12 families) carriedSETXmutations (AOA2, 57%), two were mutated inATM(A-T), and three inAPTX(AOA1). In three remaining patients, we could not find pathogenic mutations, and in one case we found, in homozygosis, theSETXp.K992R polymorphism (population frequency 1-2%). In AOA2 cases, we identified 14 novel and three reportedSETXmutations. Signs at onset were gait ataxia and facial dyskinesia, and the age ranged between 11 and 18 years. None had obvious oculomotor apraxia at the latest examination (age 14–45 years). The patient carrying the p.K992RSETXpolymorphism had a phenotype similar to that of the diagnosed AOA2 patients, while the other three undiagnosed subjects had a very late onset and a few distinguishing clinical features.Discussion and conclusions: We describe a large series of 13 AOA2 Italian patients. The phenotype was consistent with previous descriptions of AOA2, except for a higher frequency of strabism, and for the absence of oculomotor apraxia. In our survey ~60% of juvenile-to-adult cases with cerebellar ataxia, sensorimotor neuropathy and increased AFP are due to mutations in theSETXgene, and a smaller percentage toAPTXandATMgene mutations.

6 December 2019 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
ADAnnika Danielsson
Annika Danielsson
Miryam CarecchioMiryam Carecchio
Miryam Carecchio
LCLaura Cif
Laura Cif
AKAnne Koy
Anne Koy
JLJean-Pierre Lin
Jean-Pierre Lin
KTKristina Tedroff
Kristina Tedroff
Pallidal deep brain stimulation is an established treatment in dystonia. Available data on the effect in DYT-THAP1 dystonia (also known as DYT6 dystonia) are scarce and long-term follow-up studies are lacking. In this retrospective, multicenter follow-up case series of medical records of such patients, the clinical outcome of pallidal deep brain stimulation in DYT-THAP1 dystonia, was evaluated. The Burke Fahn Marsden Dystonia Rating Scale served as an outcome measure. Nine females and 5 males were enrolled, with a median follow-up of 4 years and 10 months after implant. All benefited from surgery: dystonia severity was reduced by a median of 58% (IQR 31-62, p = 0.001) at last follow-up, as assessed by the Burke Fahn Marsden movement subscale. In the majority of individuals, there was no improvement of speech or swallowing, and overall, the effect was greater in the trunk and limbs as compared to the cranio-cervical and orolaryngeal regions. No correlation was found between disease duration before surgery, age at surgery, or preoperative disease burden and the outcome of deep brain stimulation. Device- and therapy-related side-effects were few. Accordingly, pallidal deep brain stimulation should be considered in clinically impairing and pharmaco-resistant DYT-THAP1 dystonia. The method is safe and effective, both short- and long-term.

24 January 2012 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
AFAndrea Franzini
Andrea Franzini
RCRoberto Cordella
Roberto Cordella
GMGiuseppe Messina
Giuseppe Messina
CMCarlo Efisio Marras
Carlo Efisio Marras
Luigi Michele RomitoLuigi Michele Romito
Luigi Michele Romito
GBGiovanni Broggi
Giovanni Broggi

22 April 2024 in Movement Disorders
Verified
Journal Article
Open access
VDValentina Duga
Valentina Duga
RGRiccardo Giossi
Riccardo Giossi
Luigi Michele RomitoLuigi Michele Romito
Luigi Michele Romito
MSMario Stanziano
Mario Stanziano
VLVincenzo Levi
Vincenzo Levi
NNNardo Nardocci
Nardo Nardocci
Background: The evidence in the effectiveness of deep brain stimulation in children with medication‐refractory non‐degenerative monogenic dystonia is heterogeneous and long‐term results are sparse.Objectives: The objective is to describe long‐term outcomes in a single‐center cohort and compare our results with a meta‐analysis cohort form literature.Methods: We performed a retrospective single‐center cohort study including consecutive pediatric patients with non‐degenerative genetic or idiopathic dystonia treated with globus pallidus internus deep brain stimulation at our center and a systematic review and individual‐patient data meta‐analysis with the same inclusion criteria. The primary outcome was the change from baseline in the Burke‐Fahn‐Marsden Dystonia Rating Scale‐movement (BFMDRS‐M) score.Results: The clinical cohort included 25 patients with a mean study follow‐up of 11.4 years. The meta‐analysis cohort included 224 patients with a mean follow‐up of 3 years. Overall, the BFMDRS‐M mean improvements at 1 year and at last follow‐up were 41% and 33% in the clinical cohort and 58.9% and 57.2% in the meta‐analysis cohort, respectively. TOR1A‐dystonia showed the greatest and most stable BFMDRS‐M improvement in both cohorts at 1 year and at last follow‐up (76.3% and 74.3% in the clinical cohort; 69.6% and 67.3% in the meta‐analysis cohort), followed by SGCE‐dystonia (63% and 63.9% in the meta‐analysis cohort). THAP1‐dystonia (70.1% and 29.8% in the clinical cohort; 52.3% and 42.0% in the meta‐analysis cohort) and KMT2B‐dystonia (33.3% and 41.3% in the clinical cohort; 38.0% and 26.7% in the meta‐analysis cohort) showed a less pronounced or sustained response.Conclusion: Globus pallidus deep brain stimulation long‐term treatment seems effective with a possible gene‐specific differential effect. © 2024 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.

27 February 2021 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
GZGiovanna Zorzi
Giovanna Zorzi
ISIgnacio Juan Keller Sarmiento
Ignacio Juan Keller Sarmiento
FDFederica Rachele Danti
Federica Rachele Danti
BBBernabe I. Bustos
Bernabe I. Bustos
FIFederica Invernizzi
Federica Invernizzi
NMNiccolò E. Mencacci
Niccolò E. Mencacci